Stroke Treatment Device Quickly Restores Brain Blood Flow

The design also incorporated tailored radial force, refined wide cell architecture, and low coverage for rapid clot integration across different clot types. Another important feature is a tubular design with spiral cell alignment, which conforms to the blood vessel with uniform cell area, regardless of turtuosity.

Results from the recent Trevo 2 randomized embolectomy stroke device trial, involving 178 patients at 27 US and European health care facilities, demonstrated that the Trevo Retriever produced a 92% rate of restoring blood flow, versus 76.7% for the Merci Retriever, both developed by Concentric Medical (Mountain View, CA, USA), now a part of Stryker (Kalamazoo, MI, USA;). Patients with the Trevo device also produced improved US National Institutes of Health (NIH) stroke scores and were able to leave the hospital sooner.

“Our mission is to advance complete stroke care for patients worldwide. In doing so, we are committed to providing innovative, new technologies, along with robust clinical evidence to expand the field,” said Mark Paul, President of Stryker's neurovascular division. “As we saw with the Trevo 2 data, this technology is helping physicians and patients, and we are very excited to be able to facilitate advances in medical care with game-changing technology like the Trevo Pro Retriever.”

“The launch of this device is another great stride in the evolution of stroke care,” said Trevo 2 Investigator Gary Duckwiler, MD, of the University of California Los Angeles Medical Center (USA). “Concentric Medical, which is now owned by Stryker, has a long history of partnering with physicians to develop devices specifically designed to remove blood clots from a blocked artery in the brain. The new Trevo Pro Retriever is easy to use and very effective at opening blood vessels; allowing physicians to have a significant impact on clinical outcomes.”

Related Links:
Stryker
University of California Los Angeles Medical Center